Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Vimian Group AB ( (SE:VIMIAN) ).
Vimian Group AB held an Extraordinary General Meeting on June 11, 2025, where shareholders approved several key resolutions. These included adopting new Articles of Association to introduce reclassifiable and redeemable share classes for the company’s incentive program, implementing a long-term performance-based share program for employees and consultants, and updating remuneration guidelines to allow for incentive programs to be adopted by both Annual and Extraordinary General Meetings. These changes are expected to enhance Vimian’s operational flexibility and align with local laws and practices, potentially impacting its market positioning and stakeholder relations.
The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.
More about Vimian Group AB
Vimian is a global animal health company that operates in four key areas: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics. The company aims to provide innovative care solutions for animals and is headquartered in Stockholm, Sweden. Vimian serves over 17,000 veterinary clinics and laboratories across more than 80 markets, employing 1,200 people and generating annual revenues of approximately EUR 375 million.
Average Trading Volume: 445,106
Current Market Cap: SEK22.7B
Find detailed analytics on VIMIAN stock on TipRanks’ Stock Analysis page.